TIBCS 2025

Program

Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
08:30 - 08:40 Opening Ceremony
08:40 - 09:00 [Keynote Speech] Right Choice Beyond Survival: How Taiwan is Pioneering Quality and Equity in Breast Cancer Care Through Value-Based Reform
Chung-Liang Shih
09:00 - 09:30 Session(1) Early Onset Breast Cancer: Current Knowledge and Gaps
Kyong Hwa Park
09:30 - 10:00 Session (1) Role of Platinum in Adjuvant/Neoadjuvant Treatment in TNBC
10:00 - 10:40 Session (1) Redefining the Role of TKIs in HER2-Positive mBC: From Systemic Control to CNS Penetration
Nancy Lin
10:40 - 11:00 Coffee Break
11:00 - 11:40 Session (2) Navigating the Complexities of Treatment in HR+ HER2- Metastatic Breast Cancer: Tailoring CDK4/6 Inhibitors to Meet Individual Patient Needs
11:40 - 12:20 Session (2) The Practice of Treating HR+/HER2- Early Breast Cancer is Evolving: Broading the Impact of CDK4/6 Inhibitors
Peter Fasching
12:20 - 13:05 Luncheon Symposium (1) Maximizing Treatment Benefit and Overall Survival in HER2- Negative MBC
13:05 - 13:20 Coffee Break
13:20 - 14:00 Session (2) The Sustainable Efficacy of CDK4/6 Inhibitor in HR+/Her2- Node+ High Risk Early Breast Cancer
Michael Gnant
14:00 - 14:30 Session (2) Personalized Neo-Adjuvant Strategies for Hormone Receptor-Positive Early Breast Cancer
Marc Thill
14:30 - 15:10 Session (2) Choosing Wisely:TS-1 for HR+ EBC
15:10 - 15:30 Coffee Break
15:30 - 16:10 Session (2) Transforming Treatment Landscape of HR+ mBC: Integrating Genomic Biomarkers to Drive Precision Medicine
Naoto T. Ueno
16:10 - 16:50 Session (2) The Next Wave of Endocrine and Target Therapy for HR+/HER2- Metastatic Breast Cancer
Peter Schmid
16:50 - 17:30 Session (3) Unlocking the Potential of ADC: Transforming Breast Cancer Outcomes Across HER2 Expression Spectrum (MBC)
Naoto T. Ueno
17:30 - 18:00 Session (3) Current Status and Emerging Approaches in HER2+ Metastatic Breast Cancer
Giampaolo Bianchini
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
10:10 - 10:30 [TBCS-GBCC Joint Session] Axillary management following NAC: Surgical Oncologists’ point of views
10:30 - 10:50 [TBCS-GBCC Joint Session] Axillary management following NAC: Medical Oncologists’ point of views
10:50 - 11:10 [TBCS-GBCC Joint Session] Axillary management following NAC: Radiation Oncologists’ point of views
11:10 - 11:30 [TBCS-GBCC Joint Session] Wrap up: Current guidelines of Axillary management following NAC
11:30 - 12:00 [TBCS-GBCC Joint Session] Panel Discussion
14:05 - 14:30 [Young Doctors Forum] Beyond the White Coat: Challenges Facing Young Female Breast Oncologists and How to Address Them
Kelly Hunt
14:30 - 14:55 [Young Doctors Forum] Global Perspectives: Navigating Career Pathways in Breast Cancer Treatment for Young Doctors
Tristen Park
14:55 - 15:00 [Young Doctors Forum] Q&A
15:00 - 15:05 Coffee Break
15:05 - 16:30 Young Doctors Debate
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
08:10 - 08:50 Breakfast Symposium: Beyond Cancer-Related Fatigue: Exploring Immunomodulatory Strategies to Reshape Breast Cancer Care
08:50 - 09:20 Session (4) The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer
Mehra Golshan
09:20 - 09:50 Session (4) Omission of Radiation Therapy Post Breast Conserving Surgery
Boon Chua
09:50 - 10:05 Coffee Break
10:05 - 10:35 Session (4) Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy
Judy C. Boughey
10:35 - 11:05 Session (4) Setting the Standard for the Future of Cancer Surgery
Kelly Hunt
11:05 - 11:45 Session (5) Shifting Paradigms in mTNBC - Advancing Sacituzumab Towards the Frontline
Sherene Loi
11:45 - 12:25 Session (5) A New Era in the Treatment of Metastatic Triple-Negative Breast Cancer: Who, When, and Why to Use Immunotherapy and Antibody-Drug Conjugates
12:25 - 13:10 Luncheon Symposium (2) Advances in Dual HER2 Inhibition: Shaping the Future of HER2-Positive Breast Cancer Care